Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis

Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Kelly A., Shen, Jeanne, Rieger, Kerri, Wei, Mike T., Gubatan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699508/
https://www.ncbi.nlm.nih.gov/pubmed/36447766
http://dx.doi.org/10.14309/crj.0000000000000881
_version_ 1784839091110543360
author Hu, Kelly A.
Shen, Jeanne
Rieger, Kerri
Wei, Mike T.
Gubatan, John
author_facet Hu, Kelly A.
Shen, Jeanne
Rieger, Kerri
Wei, Mike T.
Gubatan, John
author_sort Hu, Kelly A.
collection PubMed
description Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal manifestations of UC are unclear. Sweet syndrome, an acute febrile neutrophilic dermatosis, is a cutaneous manifestation of inflammatory bowel disease that parallels disease activity. In this study, we present the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with UC successfully treated with ustekinumab.
format Online
Article
Text
id pubmed-9699508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-96995082022-11-28 Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis Hu, Kelly A. Shen, Jeanne Rieger, Kerri Wei, Mike T. Gubatan, John ACG Case Rep J Case Report Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal manifestations of UC are unclear. Sweet syndrome, an acute febrile neutrophilic dermatosis, is a cutaneous manifestation of inflammatory bowel disease that parallels disease activity. In this study, we present the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with UC successfully treated with ustekinumab. Wolters Kluwer 2022-11-22 /pmc/articles/PMC9699508/ /pubmed/36447766 http://dx.doi.org/10.14309/crj.0000000000000881 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Hu, Kelly A.
Shen, Jeanne
Rieger, Kerri
Wei, Mike T.
Gubatan, John
Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title_full Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title_fullStr Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title_full_unstemmed Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title_short Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
title_sort subcutaneous sweet syndrome successfully treated with ustekinumab in a patient with ulcerative colitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699508/
https://www.ncbi.nlm.nih.gov/pubmed/36447766
http://dx.doi.org/10.14309/crj.0000000000000881
work_keys_str_mv AT hukellya subcutaneoussweetsyndromesuccessfullytreatedwithustekinumabinapatientwithulcerativecolitis
AT shenjeanne subcutaneoussweetsyndromesuccessfullytreatedwithustekinumabinapatientwithulcerativecolitis
AT riegerkerri subcutaneoussweetsyndromesuccessfullytreatedwithustekinumabinapatientwithulcerativecolitis
AT weimiket subcutaneoussweetsyndromesuccessfullytreatedwithustekinumabinapatientwithulcerativecolitis
AT gubatanjohn subcutaneoussweetsyndromesuccessfullytreatedwithustekinumabinapatientwithulcerativecolitis

Ejemplares similares